Retrospective study of immediate postoperative electron radiotherapy for therapy-resistant earlobe keloids

Chun-Lei Liu1,2 · Zhi-Yong Yuan1

Received: 15 November 2018 / Revised: 25 February 2019 / Accepted: 13 April 2019 / Published online: 30 April 2019
© The Author(s) 2019

Abstract
Keloid resection followed by adjuvant radiotherapy is the most efficacious treatment for keloids. However, for earlobe keloids, an optimal protocol for the total dose and fractions of adjuvant radiation has not yet been established. We retrospectively analyzed the efficacy and safety of immediate three-fraction electron radiotherapy after operation for resistant earlobe keloids. From 2011 to 2017, three-fraction electron radiotherapy with single dose of 5 Gy was given postoperatively to 23 patients with 30 keloids in our hospital. The first fraction of adjuvant radiotherapy was administered within 2 h of surgery, and the other two sessions were completed within the next day or two. Five (16.7%) primary keloids and 25 (83.3%) recurrent keloids were examined in this study. The primary endpoint was the local control rate, which was 86.7% after a median follow-up of 26 months (14–93 months). Secondary endpoints were acute and late procedure-related complications, and no severe complications were observed after combination therapy. Our results suggest that three-fraction electron radiotherapy after excision within 2 days of surgery is a safe and effective protocol for the prevention of earlobe keloid recurrence that can also improve patient compliance and comfort.

Keywords Keloid · Electron radiotherapy · Three-fraction · Earlobe

Introduction
Keloids are a benign fibro-proliferative disease that spread beyond the original borders of a wound in response to an injury or trauma. Earlobe has been mentioned as the most common location for keloids after any injury, most commonly cosmetic piercing [1], and due to the unique characteristics of the earlobe, such as its free edge, arc-like shape, and lack of cartilage. The incidence of earlobe keloids after ear piercing has been estimated at 2.5% [25]. It often causes pain, pruritus, and tenderness, and can cause cosmetic disfigurement, impairing the quality of life. Therefore, various treatment regimens including surgery, corticosteroids injection, cryosurgery, laser therapy, and radiotherapy are recommended for keloids [6, 11, 19, 24]. Any monotherapy is avoided because of the limited success of a single treatment. For example, the recurrence rate after surgical excision alone is as high as 80% [2, 4, 7]. At the morphological level, human earlobes have an intricate anatomical structure and the average length is approximately 2 cm [3]. Exteralesional surgical excision in combination with other treatments, especially adjuvant postoperative radiotherapy, is considered to be the most efficacious protocol for resistant keloids, reducing the relapse rate to below 10% and improving patient convenience [13, 20]. However, there is no consensus on the optimal radiation dose and fractionation schedule, especially for external radiotherapy. In this study, we retrospectively evaluated the results of surgical excision combined with immediate adjuvant radiotherapy in patients with therapy-resistant keloids.
Methods

Patient characteristics

From January 2011 to July 2017, clinical data on 23 patients (8 males and 15 females) with 30 keloids of the earlobe were retrospectively reviewed, and these 23 patients were treated with surgical excision followed by immediate adjuvant electron radiotherapy. The median age of the patients undergoing treatment was 28 years (17–63 years). Four patients had never undergone any prior treatment to manage their earlobe keloids, because they also had keloids on their faces and other parts of their bodies. Patients in this situation are considered to be more likely to relapse after treatment. Other keloids had already received one or more pretreatments; that included surgical resection, corticosteroid injection, cryotherapy, Y-laser, and a combination of these treatments. All patients consented to the treatment protocol.

Surgical treatment

To receive adjuvant radiotherapy in time after surgical resection, all patients made an appointment in advance. To accurately determine the range of target for radiotherapy, surgeons need to work together with radiation oncologists to mark the locations of earlobe keloids.

Extralesional excision was performed in all keloids with local anesthesia using xylocaine 1% with adrenaline 1:100,000. Hemostasis was achieved with electrocautery, and the wounds were closed without tension. No hyper-proliferative core excision and keloids flaps were performed. All excised specimens underwent independent histologic analysis to determine the diagnosis. The patients were transferred to the Department of Radiation Oncology to develop a radiotherapy plan and receive the first treatment within 2 h of excision. Seven days after radiotherapy, the skin sutures were removed.

Radiotherapy

Adjuvant postoperative radiotherapy for all keloids was implemented within 2 h of surgical excision using a 6-MeV electron-beam, with full shielding to protect the normal tissues (Fig. 1). Before radiotherapy, radiotherapy oncologists applied 0.5 cm wax to increase the surface dose. Previous keloid cases were treated with a total radiation dose of 15 Gy that was delivered in three fractions over 3 days that was initiated on the same day as surgery. Since 2015, we have shortened the course of radiotherapy from 3 days to 2. The remaining two fractions of radiotherapy were given on the second day after surgery, and must be at least 6 h apart.

Follow-up

Patients were required to return to the hospital regularly for a face-to-face follow-up. If some patients could not return for an in-office follow-up, they were contacted by phone to confirm the success of the keloid treatment and were asked to provide pictures. Follow-up visits were scheduled at 3 months, 6 months, 1 year, and every year thereafter, as follow-up visits should extend for at least 1 year after treatment.

Fig. 1 Shield effect on dosimetry: a shows the lead shielding to protect the surrounding normal tissue; b shows a 0.5 cm wax to increase the surface dose
to improve the validity of the outcome, because only after that period is the chance of recurrence minimal [8, 29]. The primary endpoint was the local control rate. The secondary endpoints were acute and late procedure-related complications according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Acute toxicity occurred within 3 months after radiotherapy, and late toxicity occurred within 3–6 months or longer. Recurrence was defined as the presence of a new keloid scar in the treated location, with sustained growth, and classic symptoms such as pain, and itching. A hypertrophic scar was defined by raised scars that did not grow beyond the boundaries of the original wound.

## Results

Twenty-three patients with 30 keloids were entered into the study, including 5 (16.7%) primary keloids and 25 (83.3%) recurrent keloids. No keloids had been previously treated with any form of radiotherapy. All the patients were followed up and the result is shown in Fig. 2. Other patient and keloids characteristics are shown in Table 1.

At the last follow-up date, 4 (13.3%) keloids had recurred after a median follow-up of 26 months (14–93 months). Two of the lesions were in the same patient and recurred 3 months after radiotherapy. Two other keloids relapsed 9 and 19 months after radiotherapy, respectively.

One patient experienced peeling and slight hypertrophied scars (Fig. 3). The pretherapeutic symptoms were completely resolved on other patients without recurrence. There were no acute adverse effects such as delayed wound

### Table 1 Summary of patient and keloid characteristics

| Characteristic               | No. (%)       |
|-----------------------------|---------------|
| Gender                      |               |
| Male                        | 8 (35%)       |
| Female                      | 15 (65%)      |
| Median age (range)          | 28 (17–63)    |
| Anatomical location         |               |
| Unilateral                  | 16 (69.6%)    |
| Bilateral                   | 7 (30.4%)     |
| No. of keloids              | 30            |
| Left ear/right ear          | 16 (53.3%)/14 (46.7%) |
| Cause of keloids            |               |
| Ear piercing                | 21 (70%)      |
| Acne                        | 6 (20%)       |
| Trauma                      | 3 (10%)       |
| Previous treatment          |               |
| None                        | 4 (13.3%)     |
| Surgery alone               | 10 (33.3%)    |
| Cryotherapy                 | 2 (6.7%)      |
| Laser treatment             | 3 (10.0%)     |
| Combination                 | 11 (36.7%)    |
| Maximum diameter of lesion (cm) | 2.3 (1.4–3.7) |
| Duration of radiotherapy    |               |
| Three days                  | 6 (20%)       |
| Two days                    | 24 (80%)      |
| Radiotherapy schem          | 15/(3 × 5 Gy) |
| BED (Gy) (α/β = 10)         | 22.5          |

![Fig. 2](image) The local control and follow-up states of all 30 keloids: the 5-year Kaplan–Maier estimated local control was 86.7%
healing, skin ulceration, or infections. Four keloids in three patients showed mild hyperpigmentation, and no other serious late side effects, such as skin atrophy, telangiectasia, and subcutaneous fibrosis were noted by the physicians who performed the examination.

Discussion

Keloids are benign, fibro-proliferative lesions that may result in cosmetic deformities as well as decrease quality of life [8, 28]. Patients seek treatment to eradicate symptoms such as itching, pain, and burning; that cause the largest burden in keloid disease [20, 22, 24]. Adjuvant irradiation using electron radiotherapy or brachytherapy for keloids has been used for nearly a century and achieved an excellent therapeutic effect, especially for earlobe keloids (Table 2). However, to date, no widespread consensus of the optimal radiation regimen to prevent recurrence and obtain the best treatment results has been established.

In recent years, there have been extensive studies using interstitial brachytherapy for the postoperative treatment of keloids. Ping Jiang et al. [14] reported that, after a median follow-up of 49.7 months, they obtained a 92% local control rate using perioperative interstitial high-dose-rate (HDR) brachytherapy in 29 patients with 37 recurrent keloids. Eveline Bijland et al. [5] treated 238 keloids using three different HDR brachytherapy schemes including 2×9 Gy, 3×6 Gy, and 2×6 Gy, and observed an overall local control rate of 91.7% after at least 12 months of follow-up. Although few recent studies have focused specifically on external radiotherapy, good result has been reported. Song et al. treated 12 patients using electron-beam radiotherapy with a single fraction of 10 Gy [26]. No recurrence was found after a mean follow-up period of 20 months. A recent analysis reported a 96% local control rate for 145 patients with 174 lesions [20]. The schemes of postoperative radiotherapy, using a 4-MeV electron-beam, included 15 Gy administered in three fractions and 10 Gy administered in two fractions. In the present research, patients with earlobe keloids at our hospital were treated with surgical excision followed by 6 MeV electron-beam radiotherapy. After a median 26-month follow-up, we observed local control in 86.7% cases, which is consistent with that reported in other studies.
Although combining surgical excision with adjuvant radiotherapy is effective, the optimal biologic equivalent dose (BED) for the inhibition of keloid recurrence is uncertain. In the literature, the $\alpha/\beta$ value of the skin was mostly reported to be 10. Kal et al. [15] conducted a dose–response analysis of external-beam radiotherapy for keloids and recommended that the BED should be at least 30 Gy to achieve a recurrence rate of < 10%. Another meta-analysis and systematic review including 72 studies reviewed radiation-based treatments used for keloid management [18]. To achieve 90% control of keloid recurrence, they suggested a dose of more than 35 Gy for external-beam radiotherapy according to the dose–response curve. In contrast, as for brachytherapy, the BED was recommended to be approximately 20 Gy, which is sufficient. To obtain a similar risk of recurrence, Eveline Bijland et al. [5] compared three different treatment protocols. The BED could be as low as 19 Gy, but they also predicted that this dose may be the lower limit of effectiveness for the prevention of keloids. Our present results indicated that similar local control rates could be reached with a BED less than 30 Gy using electron-beam radiotherapy. In regard to different radiation modalities, no statistically significant difference was found in terms of local control between brachytherapy and electron-beam irradiation [18]. However, calculations of the BED for different radiation modalities are diverse. For brachytherapy, the algorithm of equivalent dose in 2 Gy fractions (EQD2) is an extensive application in the clinic. Further randomized controlled studies should be carried out to determine the essential biologic equivalent dose for keloid management.

A short interval time from surgery to the initiation of adjuvant radiotherapy is currently recommended. Van Leeuwen et al. [28] conducted a systemic review and found that a short-time interval of less than 7 h between keloid excision and irradiation resulted in a lower recurrence rate than that observed with longer time intervals of more than 24 h. Ping Jiang et al. [14] administered the first fraction using brachytherapy within 6 h and observed a very low risk of recurrence. We compressed this interval to less than 2 h, which is in line with previous report [12]. However, Enhamre and Hammar [9] found that the treatment success had nothing to do with the time interval between surgical resection and radiotherapy. Sakamoto et al. [23] stated that the time interval between surgical resection and adjuvant radiotherapy did not affect local control and adverse effects. The true mechanism for this remains unclear and controversial. Many studies have suggested that radiation can prevent keloidal fibroblasts from proliferating [15, 17]. This seems illogical, as surgical excision removes all keloid fibroblasts. Another explanation could be that after keloid resection, some types of cells such as collagenocyte and fibroblast that play an important role

### Table 2 Summary of results of adjuvant postoperative radiotherapy for earlobe keloids

| References | No. of patents | No. of keloids | Total dose (Gy) | Fraction scheme (Gy) | BED(Gy) ($\alpha/\beta = 10$) | Median follow-up (range) (Mos) | LC rate (%) | S and R interval |
|------------|----------------|----------------|----------------|---------------------|-----------------------------|--------------------------------|--------------|-----------------|
| HDR brachytherapy |
| Garg et al. [10] | 12 | Earlobe 17 | 15 | $3 \times 5$ | 22.5 | 26 (12–71) | 88.2 | 24 h |
| Arneja et al. [1] | 25 | Earlobe 12 | 37% | $2 \times 6$ | 19.2 | 33.6 | 96.9 | 4 h |
| Van et al. [27] | 28 | Earlobe 32 | 15 | $1 \times 13$ | 29.9 | 53 (19–95) | 75.9 | 2 h |
| Hafkamp et al. [12] | 24 | Ear 29 | 13 | $1 \times 13$ | 29.9 | 53 (19–95) | 75.9 | 2 h |
| Jiang et al. [14] | 29 | Earlobe 37 | 18 | $3 \times 6$ | 28.8 | 49.7 (7.9–91.9) | 91.9 | 6 h |
| Electronic radiotherapy |
| Present study | 23 | Earlobe 30 | 15 | $3 \times 5$ | 22.5 | 26 (14–93) | 86.7 | 2 h |
| Ogawa et al. [20] | 39 | Earlobe 47 | 15 | $3 \times 5$ | 22.5 | 18 | 95.7 | – |
| Song et al. [26] | 12 | Earlobe 16 | 10 | $1 \times 10$ | 20 | 20 (mean) | 100 | 72 h |
| Vila et al. [30] | 19 | Earlobe 20 | 15 | $3 \times 5$ | 22.5 | 40 (12–68) | 76.5 | 4 h |
| Kim et al. [16] | 27 | Earlobe 13 | 12 | $3 \times 4$ | 16.8 | 132 (132–106) | 76.9 | 24 h |
| Shen et al. [24] | 568 | Earlobe 834 | 18 | $2 \times 9$ | 34.2 | 40 (12–160) | 88.3 | 24–48 h |

BED biologic equivalent dose, Mos months, LC local control, S surgery, R radiotherapy, HDR high dose rate

---

Although combining surgical excision with adjuvant radiotherapy is effective, the optimal biologic equivalent dose (BED) for the inhibition of keloid recurrence is uncertain. In the literature, the $\alpha/\beta$ value of the skin was mostly reported to be 10. Kal et al. [15] conducted a dose–response analysis of external-beam radiotherapy for keloids and recommended that the BED should be at least 30 Gy to achieve a recurrence rate of < 10%. Another meta-analysis and systematic review including 72 studies reviewed radiation-based treatments used for keloid management [18]. To achieve 90% control of keloid recurrence, they suggested a dose of more than 35 Gy for external-beam radiotherapy according to the dose–response curve. In contrast, as for brachytherapy, the BED was recommended to be approximately 20 Gy, which is sufficient. To obtain a similar risk of recurrence, Eveline Bijland et al. [5] compared three different treatment protocols. The BED could be as low as 19 Gy, but they also predicted that this dose may be the lower limit of effectiveness for the prevention of keloids. Our present results indicated that similar local control rates could be reached with a BED less than 30 Gy using electron-beam radiotherapy. In regard to different radiation modalities, no statistically significant difference was found in terms of local control between brachytherapy and electron-beam irradiation [18]. However, calculations of the BED for different radiation modalities are diverse. For brachytherapy, the algorithm of equivalent dose in 2 Gy fractions (EQD2) is an extensive application in the clinic. Further randomized controlled studies should be carried out to determine the essential biologic equivalent dose for keloid management.

A short interval time from surgery to the initiation of adjuvant radiotherapy is currently recommended. Van Leeuwen et al. [28] conducted a systemic review and found that a short-time interval of less than 7 h between keloid excision and irradiation resulted in a lower recurrence rate than that observed with longer time intervals of more than 24 h. Ping Jiang et al. [14] administered the first fraction using brachytherapy within 6 h and observed a very low risk of recurrence. We compressed this interval to less than 2 h, which is in line with previous report [12]. However, Enhamre and Hammar [9] found that the treatment success had nothing to do with the time interval between surgical resection and radiotherapy. Sakamoto et al. [23] stated that the time interval between surgical resection and adjuvant radiotherapy did not affect local control and adverse effects. The true mechanism for this remains unclear and controversial. Many studies have suggested that radiation can prevent keloidal fibroblasts from proliferating [15, 17]. This seems illogical, as surgical excision removes all keloid fibroblasts. Another explanation could be that after keloid resection, some types of cells such as collagenocyte and fibroblast that play an important role

---

© Springer
in keloid formation in rapidly proliferate. From a radiobiological point of view, these cells should be radiosensitive, at least theoretically. As this process begins directly after the operation, it is important to start irradiation as quickly as possible by transferring the patient immediately after surgery to the radiation department. Therefore, when radiotherapy should be initiated after excision to obtain a better prognosis is yet to be investigated.

The complication results in our study indicated that radiotherapy following surgical excision is a safe treatment modality. Electron-beam radiotherapy has routinely been used for the treatment of keloids in our hospital to reduce radiation damage to the surrounding normal tissues. Although the majority of patients were concerned about carcinogenesis from irradiation, no reports suggested that postoperative radiotherapy can induce a malignant neoplasm in the earlobe after irradiating for keloids [21]. The radiotherapy dosage used in the present study was 15 Gy administered in three fractions, and the BED is 22.5 Gy, which is lower than the proposed BED of more than 30 Gy [29]. However, further prospective studies should be carried out, and longer follow-up is necessary.

It should also be noted that our study was not without limitations. First, similar to most previous studies, the number of patients included in the present study was too small (only 30 keloids). Second, most patients have previously received a variety of treatments, and the impact of these pretreatment on the outcomes is difficult to assess. Third, fewer than half of the patients returned to the hospital regularly for scheduled follow-ups, which may have led to bias in the evaluation of efficacy. Nevertheless, the major finding of our study was that not only good local control but also low acute and long-term toxicity were observed with this treatment regimen. In particular, infection complications were avoided.

**Conclusion**

In summary, immediate postoperative radiotherapy using a total of 15 Gy in three fractions was well tolerated and received without any adverse effects. This was a safe and effective protocol for the prevention of earlobe keloid recurrence. Because the treatment time was reduced from 3 days to 2 days, patients completed treatment in the outpatient department, which avoided inpatient inconvenience and increased patient compliance. Further prospective research is needed to prove the benefits and advantage of this keloid treatment regimen.

**Funding** None.

**Compliance with ethical standards**

**Conflict of interest** The authors report no conflicts of interest in this work.

**Ethical approval** The study was approved by the ethics committee of Tianjin Medical University Cancer Institute and Hospital.

**Informed consent** Before treatment, all patients signed informed consent. The pictures in the article were also used with the consent of the patient.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Arneja JS, Singh GB, Dolynchuk KN, Murray KA, Rozzelle AA, Jones KD (2008) Treatment of recurrent earlobe keloids with surgery and high-dose-rate brachytherapy. Plast Reconstr Surg 121(1):95–99
2. Arno AI, Gauglitz GG, Barret JP, Jeschke MG (2014) Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 40(7):1255–1266
3. Azaria R, Adler N, Sillen R, Regev D, Hauben DJ (2003) Morphometry of the adult human earlobe: a study of 547 subjects and clinical application. Plast Reconstr Surg 111(7):2398–2402 (discussion 403–4)
4. Berman B, Bieley HC (1996) Adjunct therapies to surgical management of keloids. Dermatol Surg 22(2):126–130
5. Bijlard E, Verduijn GM, Harmeling JX, Dehnad H, Niessen FB, Meijer OWM, Mureau MAM (2018) Optimal high-dose-rate brachytherapy fractionation scheme after keloid excision: a retrospective multicenter comparison of recurrence rates and complications. Int J Radiat Oncol Biol Phys 100(3):679–686
6. Brent B (1978) The role of pressure therapy in management of earlobe keloids: preliminary report of a controlled study. Ann Plast Surg 1:579–581
7. Cosman B, Wolff M (1974) Bilateral earlobe keloids. Plast Reconstr Surg 53(5):540–543
8. Dinh Q, Veness M, Richards S (2004) Role of adjuvant radiotherapy in recurrent earlobe keloids. Australas J Dermatol 45:162–166
9. Enhamre A, Hammar H (1983) Treatment of keloids with excision and postoperative X-ray irradiation. Dermatologica 167(2):90–93
10. Garg MK, Weiss P, Sharma AK, Gorla GR, Jagannauth W, Yaparpalvi R, Delrowe J, Beitler JJ (2004) Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation. Radiother Oncol 73(2):233–236
11. Gupta S, Sharma VK (2011) Standard guidelines of care: keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol 77(1):94–100
12. Hafkamp CJH, Lapid O, Davila Fajardo R, van de Kar AL, Koodoorder C, Stalpers LJ, Pieters BR (2017) Postoperative single-dose interstitial high-dose-rate brachytherapy in therapy-resistant keloids. Brachytherapy 16(2):415–420
13. Jiang P, Baumann R, Dunst J, Geenen M, Siebert FA, Niehoff P, Bertolini J, Druecke D (2016) Perioperative interstitial high-dose-rate brachytherapy for the treatment of recurrent keloids: feasibility and early results. Int J Radiat Oncol Biol Phys 94(3):532–536
14. Jiang P, Geenen M, Siebert FA, Bertolini J, Poppe B, Luetzen U, Dunst J, Druecke D (2018) Efficacy and the toxicity of the interstitial high-dose-rate brachytherapy in the management of recurrent keloids: 5-year outcomes. Brachytherapy 17(3):597–600
15. Kal HB, Veen RE (2005) Biologically effective doses of postoperative radiotherapy in the prevention of keloids dose–effect relationship. Strahlenther Onkol 181(11):717–723
16. Kim K, Son D, Kim J (2015) Radiation therapy following total keloidectomy: a retrospective study over 11 years. Arch Plast Surg 42(5):588–595
17. Luo S, Benathan M, Raffoul W, Panizzon RG, Egloff DV (2001) Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg 107(1):87–96
18. Mankowski P, Kanevsky J, Tomlinson J, Dyachenko A, Luc M (2017) Optimizing radiotherapy for keloids: a meta-analysis systematic review comparing recurrence rates between different radiation modalities. Ann Plast Surg 78(4):403–411
19. Norris JE (1991) The effect of carbon dioxide laser surgery on the recurrence of keloids. Plast Reconstr Surg 87:44–49
20. Ogawa R, Huang C, Akaishi S, Dohi T, Sugimoto A, Kuribayashi S, Miyashita T, Hyakusoku H (2013) Analysis of surgical treatments for earlobe keloids: analysis of 174 lesions in 145 patients. Plast Reconstr Surg 132(5):818e–e825
21. Ogawa R, Yoshitatsu S, Yoshida K, Miyashita T (2009) Is radiation therapy for keloids acceptable? The risk of radiation-induced carcinogenesis. Plast Reconstr Surg 124(4):1196–1201
22. Ragoowansi R, Cornes PG, Glees JP, Powell BW, Moss AL (2001) Ear-lobe keloids: treatment by a protocol of surgical excision and immediate postoperative adjuvant radiotherapy. Br J Plast Surg 54(6):504–508
23. Sakamoto T, Oya N, Shibuya K, Nagata Y, Hiraoka M (2009) Dose–response relationship and dose optimization in radiotherapy of postoperative keloids. Radiother Oncol 91(2):271–276
24. Shen J, Lian X, Sun Y, Wang X, Hu K, Hou X, Sun S, Yan J, Yu L, Sun X, Li W, Wang X, Guan Q (2015) Hypofractionated electron-beam radiation therapy for keloids: retrospective study of 568 cases with 834 lesions. J Radiat Res 56(5):811–817
25. Simplot TC, Hoffman HT (1998) Comparison between cartilage and soft tissue ear piercing complications. Am J Otolaryngol 19(5):305–310
26. Song C, Wu HG, Chang H, Kim IH (2014) Ha SW (2014) Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids. J Radiat Res. 55(5):912–916
27. van Leeuwen MC, Stokmans SC, Bulstra AE, Meijer OW, van Leeuwen PA, Niessen FB (2014) High-dose-rate brachytherapy for the treatment of recalcitrant keloids: a unique, effective treatment protocol. Plast Reconstr Surg 134(3):527–534
28. van Leeuwen MC, Stokmans SC, Bulstra AE, Meijer OW, Heymans MW, Ket JC, Ritt MJ, van Leeuwen PA, Niessen FB (2015) Surgical excision with adjuvant irradiation for treatment of keloid scars: a systematic review. Plast Reconstr Surg Glob Open 3(7):e440
29. Veen RE, Kal HB (2007) Postoperative high-dose-rate brachytherapy in the prevention of keloids. Int J Radiat Oncol Biol Phys 69(4):1205–1208
30. Vila Capel A, Vilar Palop J, Pedro Olive A, Sanchez-Reyes Fernandez A (2015) Adjuvance in refractory keloids using electron beams with a spoiler: Recent results. Rep Pract Oncol Radiother 20(1):43–49